$23.455
+0.2
(+0.88%)▲
Insights on Morphic Holding Inc
Revenue is up for the last 2 quarters, 521.0K → 60.23M (in $), with an average increase of 99.1% per quarter
Netprofit is up for the last 2 quarters, -39.01M → -36.21M (in $), with an average increase of 7.7% per quarter
In the last 1 year, Seagen, Inc. has given 76.9% return, outperforming this stock by 89.5%
In the last 3 years, Novo Nordisk A/s has given 26.8% return, outperforming this stock by 54.3%
3.67%
Downside
Day's Volatility :3.67%
Upside
0.0%
17.52%
Downside
52 Weeks Volatility :69.32%
Upside
62.81%
Period | Morphic Holding Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -57.56% | -2.6% | 0.0% |
6 Months | -59.49% | 2.2% | 0.0% |
1 Year | -12.63% | -4.3% | -3.4% |
3 Years | -25.88% | 19.1% | -4.7% |
Market Capitalization | 1.2B |
Book Value | $14.54 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -3.29 |
Wall Street Target Price | 59.38 |
Profit Margin | 0.0% |
Operating Margin TTM | -2341.29% |
Return On Assets TTM | -17.2% |
Return On Equity TTM | -24.95% |
Revenue TTM | 6.7M |
Revenue Per Share TTM | 0.16 |
Quarterly Revenue Growth YOY | -78.10000000000001% |
Gross Profit TTM | -31.3M |
EBITDA | -154.8M |
Diluted Eps TTM | -3.29 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.4 |
EPS Estimate Next Year | -3.88 |
EPS Estimate Current Quarter | -0.95 |
EPS Estimate Next Quarter | -1.02 |
What analysts predicted
Upside of 153.17%
Sell
Neutral
Buy
Morphic Holding Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Morphic Holding Inc | 13.97% | -59.49% | -12.63% | -25.88% | 29.17% |
![]() Moderna, Inc. | 4.93% | -38.23% | -55.68% | -49.12% | 317.85% |
![]() Regeneron Pharmaceuticals, Inc. | 2.62% | 9.54% | 7.63% | 54.66% | 119.47% |
![]() Novo Nordisk A/s | 7.75% | 29.99% | 71.36% | 209.46% | 351.9% |
![]() Seagen, Inc. | 0.13% | 10.52% | 76.89% | 25.9% | 249.5% |
![]() Vertex Pharmaceuticals Incorporated | -2.03% | 7.65% | 11.07% | 53.76% | 96.32% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Morphic Holding Inc | NA | NA | NA | -3.4 | -0.25 | -0.17 | 0.0 | 14.54 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -12.11 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 22.78 | 22.78 | 9.01 | 42.51 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 41.76 | 41.76 | 2.03 | 2.65 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.68 | 26.68 | 0.41 | 15.04 | 0.23 | 0.14 | 0.02 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Morphic Holding Inc | Buy | $1.2B | 29.17% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $29.8B | 317.85% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $87.0B | 119.47% | 22.78 | 30.47% |
![]() Novo Nordisk A/s | Buy | $458.4B | 351.9% | 41.76 | 35.11% |
![]() Seagen, Inc. | Hold | $40.0B | 249.5% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $91.4B | 96.32% | 26.68 | 35.94% |
FMR Inc
EcoR1 Capital, LLC
BlackRock Inc
Wellington Management Company LLP
T. Rowe Price Associates, Inc.
Artal Group S A
Morphic Holding Inc’s price-to-earnings ratio stands at None
Read Moreoral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
Organization | Morphic Holding Inc |
Employees | 115 |
CEO | Dr. Praveen P. Tipirneni M.D. |
Industry | Health Technology |
Asymmetric Smart Alpha S&p 500 Etf
$23.46
+0.88%
Advisorshares Alpha Dna Equity Sentiment Etf
$23.46
+0.88%
Liberty Tripadvisor Hdg-b
$23.46
+0.88%
Tempo Automation Holdings Inc
$23.46
+0.88%
Falcon's Beyond Global Inc
$23.46
+0.88%
Jaguar Global Growth Corporation I
$23.46
+0.88%
Missfresh Ltd
$23.46
+0.88%
Shuaa Partners Acquisition Corp I
$23.46
+0.88%
Rose Hill Acquisition Corp
$23.46
+0.88%